EMBECTA CORP. Cost of Revenue
EMBECTA CORP. (EMBC) reported Cost of Revenue of $118.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-07
- EMBECTA CORP. cost of goods and services sold for the quarter ending 2026-06-30 was $118.40M, a 20.33% increase year-over-year.
- EMBECTA CORP. cost of goods and services sold for the quarter ending 2026-03-31 was $94.00M, a 0.95% decline year-over-year.
- EMBECTA CORP. cost of goods and services sold for the quarter ending 2025-12-31 was $99.50M, a 5.06% decline year-over-year.
- EMBECTA CORP. cost of goods and services sold for the quarter ending 2025-09-30 was $105.50M, a 6.06% decline year-over-year.
- EMBECTA CORP. cost of goods and services sold for fiscal 2025 was $403.60M, a 4.05% increase from fiscal 2024.
- EMBECTA CORP. cost of goods and services sold for fiscal 2024 was $387.90M, a 4.58% increase from fiscal 2023.
- EMBECTA CORP. cost of goods and services sold for fiscal 2023 was $370.90M, a 4.60% increase from fiscal 2022.
- EMBECTA CORP. cost of goods and services sold for fiscal 2022 was $354.60M, a 2.82% decline from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $118.40M 10-Q · filed 2026-08-07 | $212.40M derived: sum of 2 quarters · filed 2026-08-07 | $311.90M 10-Q · filed 2026-08-07 | $417.40M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $94.00M 10-Q · filed 2026-05-05 | $193.50M 10-Q · filed 2026-05-05 | $299.00M derived: sum of 3 quarters · filed 2026-05-05 | $397.40M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $99.50M 10-Q · filed 2026-02-05 | $205.00M derived: sum of 2 quarters · filed 2026-02-05 | $303.40M derived: sum of 3 quarters · filed 2026-08-07 | $398.30M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-09-30 | $105.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $203.90M derived: sum of 2 quarters · filed 2026-08-07 | $298.80M derived: sum of 3 quarters · filed 2026-08-07 | $403.60M 10-K · filed 2025-11-25 |
| 2025-06-30 | $98.40M 10-Q · filed 2026-08-07 | $193.30M derived: sum of 2 quarters · filed 2026-08-07 | $298.10M 10-Q · filed 2026-08-07 | $410.40M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $94.90M 10-Q · filed 2026-05-05 | $199.70M 10-Q · filed 2026-05-05 | $312.00M derived: sum of 3 quarters · filed 2026-05-05 | $394.40M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $104.80M 10-Q · filed 2026-02-05 | $217.10M derived: sum of 2 quarters · filed 2026-02-05 | $299.50M derived: sum of 3 quarters · filed 2026-02-05 | $401.30M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-09-30 | $112.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $194.70M derived: sum of 2 quarters · filed 2025-11-25 | $296.50M derived: sum of 3 quarters · filed 2025-11-25 | $387.90M 10-K · filed 2025-11-25 |
| 2024-06-30 | $82.40M 10-Q · filed 2025-08-08 | $184.20M derived: sum of 2 quarters · filed 2025-08-08 | $275.60M 10-Q · filed 2025-08-08 | $375.70M derived: sum of 4 quarters · filed 2025-11-25 |
| 2024-03-31 | $101.80M 10-Q · filed 2025-05-09 | $193.20M 10-Q · filed 2025-05-09 | $293.30M derived: sum of 3 quarters · filed 2025-11-25 | $389.90M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-12-31 | $91.40M 10-Q · filed 2025-02-06 | $191.50M derived: sum of 2 quarters · filed 2025-11-25 | $288.10M derived: sum of 3 quarters · filed 2025-11-25 | $375.40M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-09-30 | $100.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $196.70M derived: sum of 2 quarters · filed 2025-11-25 | $284.00M derived: sum of 3 quarters · filed 2025-11-25 | $370.90M 10-K · filed 2025-11-25 |
| 2023-06-30 | $96.60M 10-Q · filed 2024-08-09 | $183.90M derived: sum of 2 quarters · filed 2024-08-09 | $270.80M 10-Q · filed 2024-08-09 | $368.50M derived: sum of 4 quarters · filed 2024-12-11 |
| 2023-03-31 | $87.30M 10-Q · filed 2024-05-09 | $174.20M 10-Q · filed 2024-05-09 | $271.90M derived: sum of 3 quarters · filed 2024-12-11 | $360.10M derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-12-31 | $86.90M 10-Q · filed 2024-02-09 | $184.60M derived: sum of 2 quarters · filed 2024-12-11 | $272.80M derived: sum of 3 quarters · filed 2024-12-11 | $356.10M derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-09-30 | $97.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-11 | $185.90M derived: sum of 2 quarters · filed 2024-12-11 | $269.20M derived: sum of 3 quarters · filed 2024-12-11 | $354.60M 10-K · filed 2024-12-11 |
| 2022-06-30 | $88.20M 10-Q · filed 2023-08-08 | $171.50M derived: sum of 2 quarters · filed 2023-08-08 | $256.90M 10-Q · filed 2023-08-08 | $347.50M derived: sum of 4 quarters · filed 2023-11-29 |
| 2022-03-31 | $83.30M 10-Q · filed 2023-05-12 | $168.70M 10-Q · filed 2023-05-12 | $259.30M derived: sum of 3 quarters · filed 2023-11-29 | $351.70M derived: sum of 4 quarters · filed 2023-11-29 |
| 2021-12-31 | $85.40M 10-Q · filed 2023-02-14 | $176.00M derived: sum of 2 quarters · filed 2023-11-29 | $268.40M derived: sum of 3 quarters · filed 2023-11-29 | $356.30M derived: sum of 4 quarters · filed 2023-11-29 |
| 2021-09-30 | $90.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29 | $183.00M derived: sum of 2 quarters · filed 2023-11-29 | $270.90M derived: sum of 3 quarters · filed 2023-11-29 | $364.90M 10-K · filed 2023-11-29 |
| 2021-06-30 | $92.40M 10-Q · filed 2022-08-15 | $180.30M derived: sum of 2 quarters · filed 2022-08-15 | $274.30M 10-Q · filed 2022-08-15 | |
| 2021-03-31 | $87.90M 10-Q · filed 2022-05-13 | $181.90M 10-Q · filed 2022-05-13 | ||
| 2020-12-31 | $94.00M 10-Q · filed 2022-03-16 | |||
| 2020-09-30 | $322.90M 10-K · filed 2022-12-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |